Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
Complete Title: A Phase I/II Study of Bomedemstat Combined with Maintenance Immunotherapy for Patients with Newly Diagnosed Extensive Stage Small Cell Lung Cancer (Es-Sclc)
Trial Phase: I/II
Investigator: Rafael Santana-Davila
This phase I/II trial studies the side effects of bomedemstat and maintenance immunotherapy with atezolizumab and to see how well they work in treating patients with newly diagnosed extensive stage small cell lung cancer. Bomedemstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body`s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bomedemstat and atezolizumab may work better in treating patients with extensive stage small cell lung cancer.
Keywords:
- Lung Cancer
- Lung Carcinoma, Small-Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Rafael Santana-Davila
RG1122005
NCT05191797
A Phase I/II Study of Bomedemstat Combined with Maintenance Immunotherapy for Patients with Newly Diagnosed Extensive Stage Small Cell Lung Cancer (Es-Sclc)
Lung Cancer
Lung Carcinoma, Small-Cell